

Interstitial Lung Diseases - Pipeline Insight, 2021

<https://marketpublishers.com/r/IFEAE184265AEN.html>

Date: July 2021

Pages: 60

Price: US\$ 3,000.00 (Single User License)

ID: IFEAE184265AEN

Abstracts

This report can be delivered to the clients within 2-3 Business Days

DelveInsight's, "Interstitial Lung Diseases - Pipeline Insight, 2021," report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Interstitial Lung Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Interstitial Lung Disease Understanding

Interstitial Lung Disease: Overview

Interstitial lung disease is a long-term (chronic) lung disease. It happens because of damage between the air sacs in the lung. The damage scars the lung and causes breathing problems. People with interstitial lung disease get breathless during exercise and may have a dry cough. These problems may get worse slowly or very quickly. The cause of interstitial lung disease is not known; however, a major contributing factor is thought to be inhaling environmental or occupational pollutants such as inorganic or organic dusts. People with interstitial lung disease usually go to the doctor because of shortness of breath or a cough. The doctor will probably use imaging tests of your lungs to find out the problem. Such tests include- Chest X-ray, Lung function test, CT scan, and lung biopsy.

'Interstitial Lung Disease - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Interstitial Lung Disease pipeline landscape is provided which includes the disease overview and Interstitial Lung Disease treatment guidelines. The assessment part of the report embraces, in depth Interstitial Lung Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Interstitial Lung Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Interstitial Lung Disease R&D. The therapies under development are focused on novel approaches to treat/improve Interstitial Lung Disease.

Interstitial Lung Disease Emerging Drugs Chapters

This segment of the Interstitial Lung Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Interstitial Lung Disease Emerging Drugs

AD-214: AdAlta

AD-214 is an Fc-Fusion protein that contains two AD-114 i-body molecules at the front end, that bind with high affinity to the human target, CXCR4. At the back end of AD-214 is the Fc Fragment or tail region of a traditional monoclonal antibody that will extend the half-life or duration of time in which the i-body will stay in the body. Currently it is in phase 1 stage of development for the treatment of interstitial lung disease.

Abatacept: Bristol-Myers Squibb

Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes. Currently, it is in phase 2 stage of development for the treatment of interstitial lung disease.

ATYR1923: aTyr Pharma

ATYR1923 is a potential first-in-class, disease modifying therapy for patients with severe inflammatory lung diseases with high unmet medical need. ATYR1923 works by selectively modulating Neuropilin-2 (NRP2) to downregulate the innate and adaptive immune responses in uncontrolled inflammatory disease states to resolve inflammation and prevent subsequent fibrosis. ATYR1923 is conducting a Phase 1b/2a clinical trial in pulmonary sarcoidosis, a major form of interstitial lung disease (ILD), a group of immune-mediated disorders that cause progressive fibrosis of the lung

Further product details are provided in the report.....

Interstitial Lung Disease: Therapeutic Assessment

This segment of the report provides insights about the different Interstitial Lung Disease drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Interstitial Lung Disease

There are approx. 100+ key companies which are developing the therapies for Interstitial Lung Disease. The companies which have their Interstitial Lung Disease drug candidates in the most advanced stage, i.e. phase II include, Bristol-Myers Squibb.

Phases

DelveInsight's report covers around 100+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Interstitial Lung Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravitreal

Subretinal

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Interstitial Lung Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Interstitial Lung Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Interstitial Lung Disease drugs.

Interstitial Lung Disease Report Insights

Interstitial Lung Disease Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Interstitial Lung Disease Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Interstitial Lung Disease drugs?

How many Interstitial Lung Disease drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Interstitial Lung Disease?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Interstitial Lung Disease therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Interstitial Lung Disease and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

AdAlta

Bristol-Myers Squibb

aTyr Pharma

Avalyn Pharmaceuticals

Beijing Continent Pharmaceutical

Regend Therapeutics

Reata Pharmaceuticals

FibroGen

PureTech Health

Bellerophon Pulse Technologies

OncoArendi Therapeutics

LTT Bio-Pharma

EmphyCorp

Genentech

Blade Therapeutics

Acceleron Pharma

Key Products

AD-214

Abatacept

ATYR1923

Pirfenidone inhalation

RO-0220912

Lung stem cells

Bardoxolone methyl

Pamrevlumab

Deupirfenidone

INOpulse

OATD 01

LT 0011

GDC 3280

BLD 2660

ACE 1334

Contents

- Introduction
- Executive Summary
- Interstitial Lung Disease: Overview
 - Causes
 - Mechanism of Action
 - Signs and Symptoms
 - Diagnosis
 - Disease Management
- Pipeline Therapeutics
 - Comparative Analysis
- Therapeutic Assessment
 - Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
 - Assessment by Molecule Type
 - Assessment by Stage and Molecule Type
- Late Stage Products (Preregistration)
 - Comparative Analysis
- Pirfenidone: Beijing Continent Pharmaceutical Co, Ltd.
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Mid Stage Products (Phase II)
 - Comparative Analysis
- Abatacept: Bristol-Myers Squibb
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Early Stage Products (Phase I)
 - Comparative Analysis
- AD-214 : AdAlta
 - Product Description
 - Research and Development
 - Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Interstitial Lung Disease Key Companies

Interstitial Lung Disease Key Products

Interstitial Lung Disease- Unmet Needs

Interstitial Lung Disease- Market Drivers and Barriers

Interstitial Lung Disease- Future Perspectives and Conclusion

Interstitial Lung Disease Analyst Views

Interstitial Lung Disease Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Interstitial Lung Disease

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Interstitial Lung Disease
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Interstitial Lung Diseases - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/IFEAE184265AEN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/IFEAE184265AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970